POUCHITIS
Clinical trials for POUCHITIS explained in plain language.
Never miss a new study
Get alerted when new POUCHITIS trials appear
Sign up with your email to follow new studies for POUCHITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug trial aims to ease pouch disorder symptoms
Disease control Recruiting nowThis study tests whether mirikizumab can reduce symptoms of chronic pouch inflammation in 25 adults. Participants receive the drug every 4 weeks for a year and track their symptoms. The goal is to see if it helps control the condition without needing ongoing antibiotics.
Matched conditions: POUCHITIS
Phase: PHASE4 • Sponsor: University of North Carolina, Chapel Hill • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
Hope for pouchitis sufferers: drug and diet combo under study
Disease control Recruiting nowThis study tests whether the drug guselkumab, alone or with a special diet, can help people with chronic pouchitis—a painful inflammation of the internal pouch after ulcerative colitis surgery. Twenty adults who have not responded to antibiotics will receive the treatment for 48 …
Matched conditions: POUCHITIS
Phase: PHASE4 • Sponsor: Universitaire Ziekenhuizen KU Leuven • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
New hope for kids with pouchitis: drug trial launches
Disease control Recruiting nowThis study tests a drug called vedolizumab in children with chronic pouchitis, an inflammation of an internal pouch created after bowel surgery. About 30 children will receive up to 12 infusions over about 18 months. The goal is to see if the drug can reduce symptoms and pouch in…
Matched conditions: POUCHITIS
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated May 11, 2026 20:46 UTC
-
New drug CLF065 aims to tame chronic pouchitis
Disease control Recruiting nowThis study tests an experimental drug called CLF065 for adults with chronic pouchitis, a condition causing inflammation in a surgically created internal pouch. The trial will compare weekly doses of CLF065 against a placebo to see if it safely reduces symptoms and inflammation. A…
Matched conditions: POUCHITIS
Phase: PHASE2 • Sponsor: Calibr, a division of Scripps Research • Aim: Disease control
Last updated May 08, 2026 12:04 UTC